Search results for " immune activation"

showing 2 items of 2 documents

The impact of DAA-mediated HCV eradication on CD4+ and CD8+ T lymphocyte trajectories in HIV/HCV coinfected patients: Data from the ICONA Foundation …

2021

HCV infection has been hypothesized as a contributor of poor CD4+ recovery in patients living with HIV (PLWHIV). Aim of this study was to evaluate CD4+, CD8+ cells and CD4/CD8 ratio trends before and after HCV treatment with direct acting agents (DAA) in PLWHIV. HIV/HCV patients enrolled in ICONA and HepaICONA cohorts with HIV-RNA≤50 copies/ml who achieved a sustained viral response after DAA treatment were studied. A linear regression model was used to investigate CD4+, CD8+ and CD4/CD8 changes 12 months before and after DAA treatment. A total of 939 HIV/HCV patients were included, 225 (24.0%) female, median age: 53 years (IQR 50–56). At DAA initiation, CD4+ T cell count was <350 cells/…

CD4-Positive T-LymphocytesHIV InfectionsHepacivirusCD8-Positive T-LymphocytesGastroenterologySettore MED/07chemistry.chemical_compound0302 clinical medicineCd8 t lymphocyteHIV Infection030212 general & internal medicineCoinfectionCD4; CD8; DAA; HCV/HIV; immune activationHcv clearancevirus diseasesMiddle AgedHepatitis CInfectious Diseasesmedicine.anatomical_structureCD4-Positive T-LymphocyteCohort030211 gastroenterology & hepatologyFemaleCD4 CD8 DAA HCV/HIV immune activationHumanImmune activationmedicine.medical_specialtyHCV/HIVT cellAntiviral Agentsimmune activationNO03 medical and health sciencesVirologyInternal medicinemedicineHumansIn patientimmune activation.DAAAntiviral AgentHepaciviruHepatologybusiness.industryRibavirinCD8-Positive T-LymphocyteCD8CD4CD4 Lymphocyte CountchemistryCD4; CD8; DAA; HCV/HIV; immune activation; Antiviral Agents; CD4 Lymphocyte Count; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Female; Hepacivirus; Humans; Middle Aged; Coinfection; HIV Infections; Hepatitis CbusinessCD8
researchProduct

A Vaccine Construction against COVID-19-Associated Mucormycosis Contrived with Immunoinformatics-Based Scavenging of Potential Mucoralean Epitopes

2022

Mucormycosis is a group of infections, caused by multiple fungal species, which affect many human organs and is lethal in immunocompromised patients. During the COVID-19 pandemic, the current wave of mucormycosis is a challenge to medical professionals as its effects are multiplied because of the severity of COVID-19 infection. The variant of concern, Omicron, has been linked to fatal mucormycosis infections in the US and Asia. Consequently, current postdiagnostic treatments of mucormycosis have been rendered unsatisfactory. In this hour of need, a preinfection cure is needed that may prevent lethal infections in immunocompromised individuals. This study proposes a potential vaccine constru…

PharmacologyInfectious DiseasesDrug DiscoveryImmunologymucormycosis; immunoinformatics; vaccine design; vaccine efficacy; population coverage; immune activationvaccine designpopulation coveragePharmacology (medical)vaccine efficacyimmunoinformaticsmucormycosisimmune activationVaccines
researchProduct